[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370005-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370005-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hcmv-as-an-oncomodulatory-virus-in-ovarian-cancer-implications-of-viral-strain-heterogeneity-immunomodulation-and-inflammation-on-the-tumour-microenvironment-and-ovarian-cancer-progression","HCMV as an Oncomodulatory Virus in Ovarian Cancer - Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression","","Human cytomegalovirus (HCMV) and cancer have been studied since the 1960s, with HCMV described as a highly prevalent β-herpesvirus that can establish lifelong latency and contribute to oncomodulation across multiple tumour types, including ovarian cancer. Variability in HCMV effects is linked to tumour type, viral strain, and disease stage, while HCMV’s influence on the ovarian cancer tumour microenvironment (TME) and immune regulation remains incompletely understood. This review summarizes recent developments on strain heterogeneity, TME immunomodulation, dysregulated inflammatory signalling, and potential therapeutic implications.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hcmv-as-an-oncomodulatory-virus-in-ovarian-cancer-implications-of-viral-strain-heterogeneity-immunomodulation-and-inflammation-on-the-tumour-microenvironment-and-ovarian-cancer-progression/370005/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hcmv-as-an-oncomodulatory-virus-in-ovarian-cancer-implications-of-viral-strain-heterogeneity-immunomodulation-and-inflammation-on-the-tumour-microenvironment-and-ovarian-cancer-progression/370005.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ovarian cancer often associated with poor survival outcomes?","Question",{"text":63,"@type":64},"Ovarian cancer is frequently diagnosed at late stages (Stage III or IV), when the five-year survival rate is less than 30%. The document also notes ongoing challenges such as lack of reliable early diagnostic biomarkers and effective immunotherapeutic strategies, alongside treatment resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does HCMV relate to cancer biology according to the review?",{"text":68,"@type":64},"The review describes HCMV as a persistent virus that can establish lifelong latency in CD34+ myeloid progenitor cells. It discusses that viral genes and proteins have been detected in several solid tumours and may contribute to oncomodulation through inflammation, angiogenesis, immune evasion, and tumour progression.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors may explain the variability of HCMV effects across cancers and disease stages?",{"text":72,"@type":64},"The document states that reported effects of HCMV vary between cancers, likely due to differences in tumour type, viral strain, and disease stage.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370005,1790647038,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nHCMV as an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression  \nChrissie Giatrakis 1, Apriliana E. R. Kartikasari 1, Thomas A. Angelovich 1, Katie L. Flanagan 2, Melissa J. Churchill 1, Clare L. Scott 3, Srinivasa Reddy Telukutla 1, * and Magdalena Plebanski 1, *  \nAcademic Editor: Fabian Benencia  \nReceived: 17 October 2025  \nRevised: 21 November 2025  \nAccepted: 27 November 2025  \nPublished: 2 December 2025  \nCitation: Giatrakis, C.; Kartikasari, A.E.R.; Angelovich, T.A.; Flanagan, K.L.; Churchill, M.J.; Scott, C.L.; Telukutla, S.R.; Plebanski, M. HCMVas an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression. Biomolecules 2025, 15, 1685. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biom15121685  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Accelerator for Translational Research in Clinical Trials (ATRACT) Centre, School of Health and Biomedical  \nSciences, STEM College, RMIT University, Melbourne, VIC 3083, Australia;  \n[chrissie.giatraki@gmail.com](chrissie.giatraki@gmail.com) (C.G.); [april.kartikasari@rmit.edu.au](april.kartikasari@rmit.edu.au) (A.E.R.K.);  \n[thomas.angelovich@rmit.edu.au](thomas.angelovich@rmit.edu.au) (T.A.A.); [melissa.churchill@rmit.edu.au](melissa.churchill@rmit.edu.au) (M.J.C.)  \n2 Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, NSW 2145, Australia; [katie.flanagan@health.nsw.gov.au](katie.flanagan@health.nsw.gov.au)  \n3 Clinical Discovery Translation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3050, Australia; [scottc@wehi.edu.au](scottc@wehi.edu.au)  \n* Correspondence: [srinivasareddy.telukutla@rmit.edu.au](srinivasareddy.telukutla@rmit.edu.au) (S.R.T.); [magdalena.plebanski@rmit.edu.au](magdalena.plebanski@rmit.edu.au) (M.P.)  \nAbstract  \nThe complex relationship between human cytomegalovirus (HCMV) and cancer has been of interest since the 1960s. As a highly prevalent human β-herpesvirus, HCMV establishes lifelong latency in CD34+ myeloid progenitor cells and has been implicated as an oncomodulatory virus in various cancers, including glioblastoma multiforme, breast, prostate, colorectal, and ovarian cancer (OC) . Recently, discussions have emerged regarding the classification of HCMV as an eighth oncovirus due to the persistence of its nucleic acids and proteins in many tumour types. As one of the deadliest gynaecological cancers, OC is often characterised as the ‘silent killer’ with less than half of women surviving for 5 years, a rate that drops below 20% when detected at advanced stages. Reported effects of HCMV vary between cancers, likely due to differences in tumour type, viral strain, and disease stage. While HCMV infection has been linked to poor OC patient outcomes, its impact on the OC tumour microenvironment (TME) and immune system remains less understood. Investigating HCMV’s potential oncogenic role could provide critical insights into OC progression. This review discusses recent developments on HCMV’s multifaceted roles in OC, including strain heterogeneity, immunomodulation of the TME, dysregulation of inflammatory signalling pathways, and potential therapeutic approaches targeting HCMVin anti-cancer immunotherapies.  \nKeywords: human cytomegalovirus; ovarian cancer; cancer progression; immunomodulation; inflammation; tumour microenvironment; viral strain heterogeneity; oncovirus; immunosuppression  \n1. Introduction  \n1.1. Ovaria","cbCailFeLg3B3FSX","https://ap.wps.com/l/cbCailFeLg3B3FSX","pdf",1700903,31,"English","# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Ovarian Cancer (OC)\n## 1.2. Human Cytomegalovirus (HCMV)","[{\"question\":\"Why is ovarian cancer often associated with poor survival outcomes?\",\"answer\":\"Ovarian cancer is frequently diagnosed at late stages (Stage III or IV), when the five-year survival rate is less than 30%. The document also notes ongoing challenges such as lack of reliable early diagnostic biomarkers and effective immunotherapeutic strategies, alongside treatment resistance.\"},{\"question\":\"How does HCMV relate to cancer biology according to the review?\",\"answer\":\"The review describes HCMV as a persistent virus that can establish lifelong latency in CD34+ myeloid progenitor cells. It discusses that viral genes and proteins have been detected in several solid tumours and may contribute to oncomodulation through inflammation, angiogenesis, immune evasion, and tumour progression.\"},{\"question\":\"What factors may explain the variability of HCMV effects across cancers and disease stages?\",\"answer\":\"The document states that reported effects of HCMV vary between cancers, likely due to differences in tumour type, viral strain, and disease stage.\"}]","HCMV as an Oncomodulatory Virus in Ovarian Cancer - Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression | PDF",1790186216,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40b77bb61abedac2fb53eb5d88c03f95.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0a14c0287d14bde6b84bd9998920999.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e22539e84ac5573211154289c5e5c166.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39854734bbb1cf1e4d8a3c4d650883ed.webp",980,1385]